Interview with Jean-Philippe Duc, Country Manager, Amgen Czech Republic
Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us…
Exeltis is an organization committed to innovation, excellence and healthcare.
Exeltis is the result of the natural evolution and sustained growth of the CHEMO pharmaceutical business, an integrated health sciences group. It combines the Group’s know-how and experience with the innovative spirit of Exeltis, becoming a global organization with the capacity to discover, develop, produce and market medicinal products and medical devices that can help to improve the quality of life of millions of people worldwide.
Exeltis has a portfolio of more than 300 medicines and presence in over 40 countries. The company covers a wide and varied range includes products for some of the most important therapeutic areas, such as Women’s Health, Respiratory, Dermatology, Cardiology, Central Nervous System, Ophthalmology, Oncology, Gastroenterology, Infectious diseases and Endocrinology, among others.
Contact
Exeltis Czech, s.r.o.
Želetavská 1449/9
140 00 Praha 4 – Michle, Czech Republic
Tel: +420 241 480 900
info.czech@exeltis.com
Exeltis Slovakia s.r.o.
Apollo Business Center II / Blok E – Prievozská 4D
821 09 Bratislava, Slovenská Republika
Tel: +421 908 927 882
info.slovak@exeltis.com
Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us…
Dr. Sommermeyer, you’ve spent approximately two decades working for pharmaceutical companies throughout Europe. From a personal standpoint, why did you decide to leave the industry and found a consultancy? I…
You joined this affiliate in October of 2011, having spent the preceding three years as GM for Servier Slovakia. What are the principal differences you found between these two markets?…
Dr. Novotný, in 2008, you became Managing Director for MSD for the Czech and Slovak Republics. In the very next year after your appointment, you were tasked with managing the…
Dr. Heger, you were appointed as the Czech Minister of Health in July of 2010. What challenges did you see for the Czech healthcare system, and what has been your…
Mr. Krýza, Mr. Nádvorník, between the two of you, you have over 21 years of experience at Cegedim, and have watched this company grow significantly through a series of mergers.…
Mr. Krýza, Mr. Nádvorník, between the two of you, you have over 21 years of experience at Cegedim, and have watched this company grow significantly through a series of mergers.…
Ms. Hauser, you represent what is perhaps the last major generation of medical doctors in this country that left the medical field to join the pharmaceutical business. What do you…
Mr. Krejčí, can you please begin with a broad introduction to Ewopharma, for those of our readers who are unfamiliar with the company? Ewopharma is part of a large group…
Mr. Zahradnik, you have long been an active member of the Czech generic drug makers’ association CAFF (Czech Association of Pharmaceutical Firms), chairing the organization. Dr. Zörner, executive director of…
Mr. Polach, can you please begin with an introduction to CzechBio and explicate the association’s mission on this market? CzechBio is an association of Czech biotech companies that started its…
Mr. Chadim, after Astellas was formed from the merger between Yamanouchi and Fujisawa, it became your job to lead its Czech subsidiary. Tapani Sura, your colleague at Astellas Poland, has…
See our Cookie Privacy Policy Here
